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Abstract Glucocorticosteroid (GCS) inhibition of cytokine production is a major anti-inflammatory mechanism.
However, increased production of pro-inflammatory cytokines during allergic airway inflammation has been proposed
to reduce GCS effects.This study aimed to investigate whether allergic airway inflammation due to natural allergen ex-
posure might decrease the sensitivity of granulocyte--macrophage colony-stimulating factor (GM-CSF) production to
GCS in blood cells.Blood sampleswere collected frompatientswith seasonal allergic asthma (n= 10) and rhinitis (n= 8)
andhealthy subjects (n= 9), before, during, and after thebirchpollen season.Wholebloodcultureswere stimulatedwith
LPS (10 ng/ml) and treated with budesonide (1011--107 M) for 20 h.GM-CSF levels were analysed using immunoassay.
Birch pollen exposure didnot alter LPS-stimulated GM-CSF production, although disease symptoms andblood eosino-
phils increased in the patients.There were no significant differences in budesonide inhibition of GM-CSF production by
blood cells of asthma andrhinitis patients comparedwith cells of healthy subjects before, during or after the birchpollen
season andno change in response to allergen exposure. Aconcentration of1nMbudesonide inhibited GM-CSFproduc-
tionbymorethan 50% at alltimepoints.Inconclusion, naturalallergenexposuredidnotreducethe sensitivityofGM-CSF
production to GCS inhibition in blood cells of seasonal allergic asthma and rhinitis patients.r 2002 Elsevier Science Ltd.
Allrights reserved
Available online athttp://www.sciencedirect.com
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Increased production of pro-in£ammatory cytokines,
such as interleukin-2 (IL-2), IL-4 and IL-13 during airway
in£ammation has been proposed to reduce the e¡ects
of glucocorticosteroids (GCS) and induce the GCS resis-Received 5 November 2001, accepted in revised form19March 2002.
Correspondence shouldbe addressed to: Susanne Larsson, c/oKatarina
Turesson,Department of Respiratory Medicine, Lund University
Hospital, 22185 Lund, Sweden.Fax: +46 4614 67 93;
E-mail: susannelarsson.lund@telia.comtance observed in certain asthma patients (1,2). Pre-
treatment of mononuclear blood cells from healthy sub-
jects with IL-2 and IL-4 in vitro reduces the sensitivity of
granulocyte ^macrophage colony-stimulating factor
(GM-CSF) production to GCS inhibition (3,4), and other
pro-in£ammatory cytokines e.g. IL-13 or tumour necro-
sis factor-alpha (TNF-a) can also reduce GCS e¡ects
(2,5). The capacity for production of these pro-in£am-
matory cytokines may be elevated by mononuclear
blood cells of patients with mild asthma and rhinitis,
especially after allergen exposure (6,7).These ¢ndings in-
dicate that endogenous in£ammatory mediators may
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inhibition.
GCS inhibition of cytokine production is an anti-in-
£ammatory mechanism, which might be of great impor-
tance in the treatment of asthma and allergic rhinitis (8,
9).Reduced GCS inhibition of pro-in£ammatory and eo-
sinophilopoietic cytokines, such as GM-CSF, might
therefore have negative consequences for the outcome
ofGCS therapy.Whether the sensitivity of cytokine pro-
duction to GCSmay be reduced during pollen exposure
due to an allergen-induced increase in pro-in£ammatory
in£ammatory mediators is not known. In the present
study, we therefore compared the sensitivity of GM-
CSF production to GCS inhibition in blood cells of pa-
tients with seasonal allergic asthma and rhinitis before,
during, and after natural allergen exposure, in order to
examine whether increased production of endogenous
in£ammatory mediators may decrease the sensitivity of
cytokineproduction toGCS.GM-CSFwas selected since
it is an eosinophilopoietic cytokine (10,11), the LPS-stimu-
latedproduction of this cytokine is very sensitive toGCS
(12,13) and its sensitivity to GCS inhibition changes in re-
sponse to the pro-in£ammatory cytokines IL-2 and IL-4
(3,4).
MATERIALSANDMETHODS
Study design
Three parallel groups of asthmatic, rhinitic, and healthy
menwere studiedduring1year.Patients andhealthy con-
trols were recruited from Lund University Hospital and
by advertisement in a local newspaper. Blood samples
were collected before (March), at the beginning (late
April) and 2 weeks into (mid-May) the birch pollen sea-
son, at the end of the grass pollen season (August), in
the autumn (October) and winter (December) of 1998,
in Lund, Sweden.Variations of in vitro GM-CSF produc-
tion and GCS (budesonide) e¡ects on GM-CSF produc-
tion were studied in whole blood cultures. In addition,
asthma and rhinitis symptoms, blood cell numbers and
di¡erentials were recorded at all visits. The study was
approved by the University Hospital’s ethics committee
and all patients and controls gave their written consent.
Study subjects
Tenmale patients (age 26^45 years; median 36.5) with a
history of allergic asthma according to the ATS-de¢ni-
tion, and eight male patients (age 22^44 years; median
28) with a history of allergic rhinitis were included.They
all had a historyof birch pollen allergy formore than two
seasons and a positive skin-prick test to birch pollen.The
asthma patients had FEV1of 83^100% of predicted (med-
ian 92). All patients were skin-prick tested against birch,
timothy, mugworth, dog, cat, D. Pteronyss and D. Farinae(ALK, Denmark). Four rhinitis and four asthma patients
were skin-prick positive to grass pollen (timothy). Pa-
tients were excluded if they had a history of allergy to
house dust mite or furred animals, received hypo-sensi-
bilisation therapy, or any medication other than short-
acting b2-agonists.None of the patients had used gluco-
corticosteroids, oral or inhaled, or anti-allergy medica-
tion within at least 2 months prior to the ¢rst blood
sampling.Most of the asthma patients also had a history
of birch pollen allergic rhinitis, and are therefore termed
asthma^rhinitis. None of the rhinitis patients had a his-
tory of asthma.Nine healthymen (age 21^38 years;med-
ian 27) without any known allergy, asthma, rhinitis or
eczema were included as controls.None of the enrolled
subjectswere smokers. Subjects planning travels outside
the Northern hemisphere were not included. Women
were excluded due to indications that cytokine produc-
tion may vary during the menstrual cycle (14,15). During
the pollen season, loratadin tablets (Clarityns, 10mg/
day; Schering-Plough) and levocabastin eye drops (Livos-
tins, 0.5mg/ml, one drop/eye, two to four times daily;
Janssen-Cilag) were allowed as rescuemedication for se-
vere rhinitis symptoms. Asthma patients were also al-
lowed to use short-acting, inhaled b2-agonists when
needed.
Upper and lower airway symptomscores
At each visit all subjects, patients and healthy controls,
were asked to grade their rhinitis symptoms (sneezing;
congestion; runny nose) during the last week as no
symptoms (0), mild (1), moderate (2) or severe (3). A to-
tal upper airway symptom score with a maximum of 9
was calculated. All subjects were also asked to grade
their asthma symptoms (shortness of breath or chest
tightness; wheeze; cough; shortness of breath when
walking or exercising; waking up at night due to short-
ness of breath) on a similar scale. A total lower airway
symptom score with a maximum of 15 was calculated.
Medication use, colds and other illnesses were also re-
corded.
Blood sampling
Venous blood was collected into sterile, heparin-con-
taining Venojects tubes (sodium heparin,15 IU/ml) at six
visits during 1 year (March, April, May, August,October
and December, 1998). Blood was collected between 8
and 10 a.m., always at the same time for each subject,
and from all subjects within1week in each sampling per-
iod. Patients and controls were asked not to drink alco-
hol later than 24h and not to use acetylsalicylic acid or
paracetamol later than 48h before blood sampling. On
each sampling day, blood samples were collected from
subjects representing all three study groups to get simi-
ALLERGENEFFECTSONGLUCOCORTICOSTEROIDSENSITIVITY 929lar day-to-day variation in pollen exposure in the di¡er-
ent groups. The samples at visit 3 were taken 2 weeks
after the samples at visit 2.
Whole blood cultures
The blood samples were diluted1: 5 in sterile RPMI1640
with HEPES bu¡er (25mM) and L-glutamine and supple-
mented with penicillin (100U/ml) and streptomycin
(0.1mg/ml) (Life Technology, Rockville, U.S.A.). Aliquots
of1mlwere then incubated in 24-well culture plateswith
or without lipopolysaccharide (LPS; 10ng/ml; E. coli
0.26:B6, Difco, Detroit, U.S.A.) and budesonide (1011^
107M; AstraZeneca R&D, Lund, Sweden), at 5% CO2,
371C, 98% RH. After 20h, the cell culture plates were
centrifuged for 10min, at 1500 rpm (500g), at 41C. The
cell-free supernatants were collected and stored at
701C until analysis. Proceeding the present study, LPS
dose^response and time kinetics were studied for sev-
eral cytokines, including GM-CSF, and compared with
cultures of separated mononuclear blood cells. Based
on these experiments, the optimal dose of LPS (10ng/
ml) and incubation time (20h)were selected for the pre-
sent study.
GM-CSF analysis
To analyse GM-CSF levels in the whole blood superna-
tants an ELISA was developed. Brie£y, 96-well micro
plates were coated over night with a monoclonal anti-
body (1mg/ml; M-500A-E; Endogen,Woburn,U.S.A.) in a
carbonate bu¡er of pH 9.7.The coating antibody was re-
moved and the plates were blocked with 4% BSA in PBS
for at least 1h. After three washes with TRIS +0.2%
Tween-20, samples or recombinant standard (7.8^
500pg/ml; Endogen, Woburn, U.S.A.) were added to-
gether with biotinylated detection antibody (0.25mg/ml
in PBSwith 4%BSA;M-501-B; Endogen,Woburn,U.S.A.).
The plates were incubated for 2h and then washed.
Streptavidin-conjugated horseradish peroxidase and tet-
ramethylbenzidine-peroxidase were used for colour de-
velopment. Absorbance was measured at 450nm with
wavelength correction at 540nm. Sample concentra-
tions were calculated from the standard curve using
computer softwarewith a four-parameter logistic curve
¢t. Inter-assay variation of internal controls was11% CV.
Heparin did not interfere with the assay. The detection
level of the assay was 7.8 pg/ml. All samples were ana-
lysed using antibodies from the same batches.
Calculation of GM-CSF levels
The whole blood cultures were obtained by diluting the
blood ¢ve times in cell culture medium. Therefore, the
cultures contain one-¢fth of endogenous blood plasmaandneed to be assayed for baselineplasma levels of cyto-
kines to obtain true values of stimulated cytokine pro-
duction. In the present study GM-CSF was detected in
unstimulated cultures of blood of nine of the 27 subjects
(two healthy, four rhinitis, and three asthma subjects).
All these subjects also had detectable levels of GM-CSF
in their plasma at all six visits that did not vary between
visits (16).The GM-CSF levels in the unstimulated blood
cultures were equal to one-¢fth of the plasma GM-CSF
levels of the same subjects, and are thus likely to have
originated from plasma and do not represent the unsti-
mulated production of GM-CSF. These GM-CSF levels
were considered as baseline levels derived from plasma
and subtracted from LPS-stimulated GM-CSF levels in
control cultures before the e¡ect of budesonidewas cal-
culated.GM-CSF levels are expressed as mean and stan-
dard error of themean (SEM).
Statistical analysis
Eosinophil numbers, andGM-CSF productionwere com-
pared using mixed linear models with visit and group as
¢xed e¡ects and patient (group) as random e¡ect (re-
peated measure ANOVA; SAS computer software, ver-
sion 6.12).Pair-wise comparisonswereperformedusing t-
type tests (SASProcMixed).P-valueso0.05wereconsid-
ered signi¢cant.The e¡ect of budesonide on LPS-stimu-
lated GM-CSF production was calculated as per cent of
control, i.e. LPS-stimulatedGM-CSF production in a cul-
ture without budesonide. Data are presented as mean
and standard error of the mean (SEM). The budesonide
doses at which maximum inhibition of GM-CSF produc-
tionwas achievedwere comparedbetween studygroups
and sampling periods using Kruskal^Wallis test.P-values
o0.05 were considered signi¢cant.
RESULTS
Pollen counts
According to local pollen reports, birch pollen counts
were moderate or high (4100 birch pollen grains/m3
air) during theweekbeforevisit 2 (April), peaked at very
high levels (41000 birch pollen grains/m3 air) during visit
2 and declined after visit 3 (mid May) (data not shown).
Grass pollen counts peaked in late June (4100 grass pol-
len grains/m3 air), but were present from late May until
August (visit 4).
Allergy symptoms and eosinophil numbers
Upper airway symptoms increased signi¢cantly at visits 2
and 3 in the rhinitis patients (Po0.001) and at visit 3 in
the asthma-rhinitis patients (Po0.001) compared with
those at visit1. Lower airway symptoms increased signif-
icantly at visit 3 in both asthma-rhinitis (Po0.001) and
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FIG 1. Upper andlower airway symptom scoresinbirchpollen
allergic rhinitics, asthmatic^rhinitic and healthy controls before
(visit 1: March), during (visit 2: April; visit 3: May) and after (visit
3^6: August, October, December) the birch pollen season in
Lund,Sweden,1998.Thetotalmaximumscoreswere 9 for upper
respiratory symptoms and15 for lower respiratory symptoms.
930 RESPIRATORYMEDICINErhinitis patients (Po0.001) comparedwith these at visit1
(Fig.1).FEV1in the asthma-rhinitis patients didnotchange
signi¢cantly between visits (Po0.078) (data not shown).
Peripheral eosinophil numbers increased signi¢cantly at
visits 2 and 3 in asthma^rhinitis patients (P=0.029;
Po0.001), and at visit 3 in rhinitis patients (P=0.006)
compared with those at visit 1. The asthma^rhinitis
patients had signi¢cantly higher eosinophil numbers
than the rhinitis patients (P=0.029) (Table 1).
Monocyte, lymphocyte, neutrophil and total leukocyte
numbers did not di¡er signi¢cantly between groups or
visits (data not shown).TABLE1 Circulatingeosinophilnumbers.Values are expressed a
Visit1
(March)
Visit 2
(April)
Vi
(M
Eosinophils (109/L)
Asthma^rhinitis 0.21 (0.03) 0.32 (0.03) 0.52
Rhinits 0.17 (0.03) 0.22 (0.03) 0.31
Health 0.29 (0.05) 0.24 (0.04) 0.22Budesonide e¡ects on GM-CSF production
There were no signi¢cant di¡erences in LPS-stimulated
GM-CSF production between visits within any group,
i.e. LPS-stimulated GM-CSF production during natural
allergen exposure did not di¡er signi¢cantly from GM-
CSF production during allergen-free periods.
In addition, there were no signi¢cant di¡erences in
LPS-stimulated GM-CSF production between the asth-
ma^rhinitis (19.3 (1.8) pg/ml) and the rhinitis (16.2 (1.3)
pg/ml) groups compared with the control group (21.6
(2.0) pg/ml; P=0.59, P=0.99). LPS-stimulated GM-CSF
production was below the detection limit of the assay
in cultures of blood obtained from three asthma^rhinitis
patients at all visits. In blood cell cultures from two asth-
ma^rhinitis patients, one rhinitis patient, and four
healthy subjects,GM-CSF productionwas below the de-
tection limit of the assay at one or twovisits.Budesonide
inhibition of LPS-stimulated GM-CSF production was
therefore compared with blood culture samples from
¢ve asthma^rhinitis patients, seven rhinitis patients and
¢ve healthy subjects from all visits. Budesonide caused a
concentration-dependent inhibition of GM-CSF produc-
tion by cells from all these patients and healthy subjects
at all visits.Themean dose^response curves for the bu-
desonide inhibitory e¡ects in the asthma-rhinitis, the
rhinitis, and the control groups overlapped at all visits
(Figs 2(a^ f)). The budesonide doses at which maximum
inhibition of GM-CSF production was achieved did not
di¡er between patients and healthy controls or between
visits (P40.05). A concentration of 1nM budesonide in-
hibited GM-CSF production by 50% or more in blood
cells of patients as well as healthy subjects at all visits.
DISCUSSION
In the present study, we have demonstrated that
natural allergen exposure does not diminish the sensitiv-
ity of GM-CSF production by blood cells from allergic
asthma and rhinitis patients to GCS inhibition in vitro.
These data are of interest with respect to the mechan-
isms of GCS action and the therapeutic use of these
drugs.
Patients with birch pollen allergic asthma and rhinitis
develop allergic airway in£ammation during the re-smean and (SEM)
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FIG. 2.(a^f) GCSinhibitionof GM-CSF productioninculturesofwholeblood fromseasonalallergic asthma-rhinitispatients (n= 5),
seasonal allergic rhinitis patients (n= 7) and healthy subjects (n= 5).Cultures of whole bloodwere obtained before a) (visit1;March),
duringb andc) (visits 2^3;April andMay) and after (d^f) (visits 4^6; August,October andDecember) thebirchpollen seasonof1998 in
Lund,Sweden.Thebudesonide e¡ecton LPS-stimulatedGM-CSF productionwas calculated aspercentofcontrol, i.e.LPS-stimulated
GM-CSF production in a culturewithout budesonide.Data are presented asmean and standard errorof themean.
ALLERGENEFFECTSONGLUCOCORTICOSTEROIDSENSITIVITY 931stricted time period when birch pollen is present.These
patients are therefore especially useful in studies com-
paring allergic mechanisms during symptomatic and
asymptomatic periods of allergic disease. The patients
with asthma and rhinitis enrolled in the present study,had increased airway symptoms and blood eosinophil
numbers during the birch pollen season.The increase in
these parameters indicated that allergic in£ammation
was indeed developed in response to natural allergen ex-
posure.
932 RESPIRATORYMEDICINEGM-CSF is a cytokine that induces proliferation and
di¡erentiation of granulocytic and monocytic stem cells
(10) and stimulates eosinophil activity and survival (11).
GM-CSF may therefore contribute to the eosinophilic
airway in£ammation observed in asthma and allergic rhi-
nitis patients. Another reason for studyingGM-CSF pro-
duction is that the production of this cytokine is very
sensitive toGCS inhibition (12,13) and theGCS sensitivity
changes in response to the pro-in£ammatory cytokines
IL-2 and IL-4 (3,4). IL-2 and IL-4 and other pro-in£amma-
tory cytokines are produced at increased levels by blood
cells from allergic individuals during the allergen season
(6).
In the cultures of wholeblood obtained from the asth-
ma^rhinitis and rhinitis patients in the present study,
LPS-stimulated GM-CSF production did not di¡er from
GM-CSF production in cultures of whole blood from
healthy subjects and was not altered due to birch pollen
exposure. Although cells in culturemay exhibit functions
not fully concordant with those in vivo (17), we demon-
strated that GM-CSF levels in plasma of these patients
did not change either (16).Thus, neither in vivo, nor in vitro
GM-CSF production was altered by natural allergen ex-
posure in the current study.
Isolated mononuclear blood cells are commonly used
in studies of cytokine production. In the present study,
however, whole blood cultures were selected instead of
cultures of separated mononuclear blood cells for sev-
eral reasons.Whole blood cultures are much quicker to
set up than cultures of isolated blood cells. This di-
minishes the time from blood sampling to experiment
and whole blood cultures give very reproducible results
when cytokine production is studied (18,19). In addition,
blood serum with endogenous proteins, such as in£am-
matorymediators andcytokines, ismaintainedin the cell
cultures, and all blood cell types are present at physiolo-
gical ratios.However, levels of cytokines already present
in the blood samplesmay in£uence the baseline cytokine
levels in the whole blood cultures and need to be care-
fully monitored and corrected for if in vitro cytokine
production is studied. Hence, in the present study
plasma GM-CSF levels were analysed and corrected for,
as described in methods. Since cell composition may
vary between various sampling periods, white blood cell
numbers and di¡erentials need to be monitored as well.
In the current study, no other blood leukocytes
(monocytes, lymphocytes or neutrophils) than eosino-
phils di¡ered signi¢cantly between study groups and
sampling periods. What also might be a disadvantage
with whole blood cultures is that cell concentrations in
the cell cultures are lower compared with cultures of
isolated cells and thereby give lower concentrations
of produced cytokines that in some cases might be
di⁄cult to analyse. Still, whole blood cultures are
more similar to in vivo conditions than cultures of isolated
cells.No reductions in GCS inhibition on GM-CSF produc-
tion by blood cells of allergic subjects were demon-
strated in the present study, despite increased airway
symptoms andbloodeosinophilia.Bothduringnatural al-
lergen exposure and during allergen-free periods a con-
centration of 1nM budesonide inhibited GM-CSF
production by at least 50% and the maximal inhibitory
e¡ects of budesonide on GM-CSF production were
reached at 10nM. Although examined in small groups of
patients, the high reproducibilty of the dose^response
e¡ects of budesonide on GM-CSF production at the dif-
ferentvisits and in the di¡erent studygroups strengthens
the results. Thus, the sensitivity of GM-CSF production
toGCS in blood cells frompatientswith seasonal allergic
asthma and rhinitis seems not to diminish due to in-
creased production of in£ammatory mediators and cy-
tokines during allergen exposure, or di¡er between
patients and healthy controls.These results suggest that
it is possible that levels of in£ammatory mediators high
enough to decrease GCS e¡ects are not reached in vivo
and that other mechanisms aremore important in caus-
ing GCS resistance.This has, however, to be more care-
fully investigated in GCS-resistant patients.
The GCS concentrations used were selected with re-
ference to clinical studies. After inhalation of a clinically
relevant dose of budesonide (500mg), the blood concen-
tration is approximately 1nM for several hours (20),
whereas the concentration in lung tissue is ten times
higher (21). In the present study, 1nM budesonide inhib-
ited GM-CSF production by at least 50% in blood cells
from asthmatic^rhinitic, rhinitic, and healthy subjects
at all visits, and no di¡erenceswere observed in the inhi-
bitory e¡ects of budesonide before, during, and after an
intense pollen season.This suggests that inhalation ther-
apy with GCSmight diminish the production of GM-CSF
byblood cells from asthma andrhinitis patientsboth dur-
ing asymptomatic and symptomatic periods.
In conclusion, the sensitivity of the pro-in£ammatory
and eosinophilopoietic cytokine GM-CSF to GCS was
not diminished by naturally induced allergic airway in-
£ammation. This is in agreement with the knowledge
that GCS therapy is very e⁄cient in the majority of pa-
tients with allergic asthma and rhinitis.
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